Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Open Access
- 6 February 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 7 (3), e007338
- https://doi.org/10.1161/jaha.117.007338
Abstract
Vitamin K antagonists (VKAs) were first introduced in the 1920s from studies on the “hemorrhagic” effect of spoiled sweet clover consumption by cattle1 and have evolved ever since to the cornerstone of oral anticoagulation therapy. The most commonly used VKA in the United States is warfarin, while in some European countries acenocoumarol and phenprocoumon are commonly used.2 VKAs exhibit their anticoagulant effect by inhibiting the vitamin K epoxide reductase complex subunit 1 in the liver. This enzyme catalyzes the post‐translational modification of vitamin K–dependent proteins. Inhibition of vitamin K epoxide reductase complex subunit 1 results in impaired synthesis of coagulation factors II (prothrombin), VII, IX, and X as well as of anticoagulant proteins C, S, and Z.3 The primary indications for VKA use are prophylaxis and treatment of venous thromboembolic disease (VTE, which includes deep vein thrombosis and pulmonary embolism) and of thromboembolic complications associated with atrial fibrillation (AF) and/or mechanical cardiac valves.This publication has 145 references indexed in Scilit:
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Cancer and renal insufficiency results of the BIRMA studyBritish Journal of Cancer, 2010
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood, 2010
- Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In VivoCell, 2009
- Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2008
- Triggers, targets and treatments for thrombosisNature, 2008
- Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulationProceedings of the National Academy of Sciences of the United States of America, 2007